AIBILI - Association for Innovation and Biomedical Research on Light and Image is a Research Technology Organisation in the health area dedicated to the development and clinical research of new products for medical therapy and diagnostic imaging.
It is a private non-profit organisation, founded in 1989, established to support translational research and technology transfer in the health area.
AIBILI is certified by ISO 9001 since 2004. It is certified for the following activities: performance of clinical studies; planning, coordination, monitoring of clinical research activities; health technology assessment; grading of eye exams; research and development in new technologies for medicine in the areas of imaging, optics and photobiology; preclinical studies of new molecules with potential medical use; and data centre activities.
AIBILI has the ECRIN Data Centre Certification, meeting the ECRIN requirements for IT and Data Management within clinical trials.
Clinical trials are performed in accordance with ICH Guidelines for Good Clinical Practice (GCP), European and national applicable legislations and regulations.
Pharmacovigilance: Updates on drug safety is a quarterly publication issued by the Portuguese Central Regional Pharmacovigilance Unit (UFC) delivering to patients and healthcare professionals information on the risks and safe use of medicines.
Farmacovigilância: Atualizações de segurança de medicamentos é uma publicação trimestral editada pela Unidade de Farmacovigilância do Centro (UFC) com o objetivo de disponibilizar informação de segurança dos medicamentos aos utentes e profissionais de saúde
Please find here the interview in the TecnoHospital edition of May/June 2016.
British researchers involved in an observational study consisting of 20,258 patients from the NHS’ (National Health Service) Diabetic Eye Screening Programme have announced their first set of results at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, USA. The study’s team of researchers qualified all of the available technologies that met their eligibility criteria before submitting them for independent evaluation. Retmarker was the only European technology to be approved by the study based on its adequate sensitivity for detecting referable retinopathy in a high-volume clinical setting when compared with existing quality-assured, real-world methods that rely on human graders. Additionally, Retmarker showed adequate specificity that qualifies it as a more cost-effective alternative. Please find here the Press Release.